Veröffentlichungsdatum: 20 April 2020
Projektträger – zwischengeschaltetes Finanzinstitut
ESTEVE HEALTHCARE SL
The project will finance the neuroscience Research, Development and Innovation (RDI) programme of Esteve, a Spanish international pharmaceutical company, in the period 2019-2022.
The aim is to finance RDI activities carried out in various therapeutic areas such as neurology, psychiatry and pain management. The EIB loan will also cover expenditures into innovative manufacturing processes and IT expenses related to the company's digitalisation. The project will be managed from the company's headquarters in Barcelona (Spain).
- Industrie - Verarbeitendes Gewerbe/Herstellung von Waren
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 110 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 222 million
Investments are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2014/52/EU amending Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The EIB's services will verify details during the project due diligence.
Unterzeichnet - 17/12/2019
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).